The 10-second takeaway
For the quarter ended March 31 (Q1), ICU Medical beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share dropped.
Margins dropped across the board.
ICU Medical reported revenue of $75.5 million. The five analysts polled by S&P Capital IQ wanted to see revenue of $74.4 million on the same basis. GAAP reported sales were 5.7% higher than the prior-year quarter's $71.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.53. The four earnings estimates compiled by S&P Capital IQ forecast $0.48 per share. GAAP EPS of $0.53 for Q1 were 7.0% lower than the prior-year quarter's $0.57 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 46.3%, 280 basis points worse than the prior-year quarter. Operating margin was 15.1%, 210 basis points worse than the prior-year quarter. Net margin was 10.1%, 120 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $79.6 million. On the bottom line, the average EPS estimate is $0.58.
Next year's average estimate for revenue is $322.5 million. The average EPS estimate is $2.58.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 75 members out of 90 rating the stock outperform, and 15 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give ICU Medical a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ICU Medical is buy, with an average price target of $53.75.
The healthcare investing landscape is littered with also-rans and a few major winners. Is ICU Medical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add ICU Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.